Drugs /

pmd-026

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the serine/threonine kinase p90 ribosomal S6 kinase (p90RSK; RSK) subtypes 1-4, with high selectivity for RSK subtype 2 (RSK2), with potential antineoplastic activity. Upon administration of the RSK1-4 inhibitor PMD-026, this agent targets and inhibits the RSK subtypes, thereby inhibiting RSK-mediated signaling. This prevents the phosphorylation and activation of the transcription factor Y-box binding protein-1 (YB-1) and leads to cell cycle arrest, an induction of apoptosis, and an inhibition of tumor cell proliferation in RSK-expressing tumor cells. RSK is overexpressed in a variety of cancers, especially in triple negative breast cancer (TNBC). It plays a key role in tumor cell proliferation, differentiation, survival, and metastasis.

Clinical Trials

View Clinical Trials for pmd-026

Pmd-026 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pmd-026, 1 is phase 1 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for pmd-026 clinical trials.

Breast carcinoma is the most common disease being investigated in pmd-026 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pmd-026
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pmd-026 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pmd 026, pmd026, rsk inhibitor pmd-026, rsk1-4 inhibitor pmd-026
Drug Target(s) [2]:
RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6
NCIT ID [1]:
C166135

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.